AHA23: Clinics in the U.S. are projected to save more than 400 hours per year using artificial intelligence (AI) applied to LINQ II™ ICMs that reduce false alerts New data presented today at the American Heart Association’s (AHA) Scientific Sessions 2023 show false alert reductions of more than 91% on […]
Coronary/Structural Heart
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
ANN ARBOR, Mich., Nov. 13, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the presentation of results from a pre-specified, exploratory analysis of CLEAR Outcomes at the 2023 American Heart Association (AHA) Scientific Sessions. Results were also simultaneously published in Circulation which can be accessed here. “The analysis presented at AHA and […]
HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
Southlake, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an AI-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that its MyoVista® wavECGTM has been selected by Cardiact Ltd […]
Ethris and Heqet Therapeutics Announce Collaboration to Develop RNA-based Therapeutics for Heart Attack and Heart Failure
Collaboration will harness the potential of non coding RNAs (ncRNAs) in regenerating heart tissue Ethris will contribute its proprietary SNaP LNP platform for precise ncRNA delivery while Heqet Therapeutics will lead preclinical and clinical development Ethris to receive milestone and royalty payments, highlighting the commitment of both companies to advance […]
CorVista Health Announces AHA Presentation of Machine Learning to Detect Pulmonary Hypertension at Point-of-Care
WASHINGTON–(BUSINESS WIRE)– #ML–CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, is pleased to announce the presentation of Machine Learning to Detect Pulmonary Hypertension data at AHA. “We are pleased to present this important data at this year’s AHA meeting.” said Don Crawford, President and CEO of CorVista Health. “Pulmonary hypertension is a challenging condition to diagnose, especially early in the disease progression. This pres
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
New Repatha® (evolocumab) Data Show No Decline in Cognitive Function Associated With Very Low Levels of LDL-C Olpasiran Research Provides Further Insights Into Cardiovascular Risks Associated With Elevated Lp(a) Amgen Provides Updates on Efforts to Advance Bold Ambition of Halving the…
Artivion Announces Completion of Enrollment in PERSEVERE Trial
ATLANTA, Nov. 9, 2023 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed enrollment in the PERSEVERE clinical trial. The PERSEVERE trial is a prospective, multicenter, non-randomized…
Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension
PALO ALTO, Calif.–(BUSINESS WIRE)–Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension. The Paradise system is intended as an adjunctive treatment […]
Xenter Unveils Groundbreaking Investigational Dual Sensor Wireless GuideWire for Minimally Invasive TAVR Procedures at TCT 2023
DRAPER, Utah–(BUSINESS WIRE)–Xenter, Inc. (Xenter.io) announced the recent unveiling of its groundbreaking dual sensor investigational guidewire for TAVR procedures at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference in San Francisco, CA. Xenter introduced the first-of-its-kind wireless guidewire designed for use during transcatheter aortic valve replacement (TAVR) procedures that aims to collect an extensive range of crucial real-time data points to serve as an aortic regu
Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients
CHICAGO–(BUSINESS WIRE)–Family Medicine Specialists has selected Cardio Diagnostics’ tests to identify patients at risk for coronary heart disease events.
Recent
New Study Highlights Safety and Efficacy Profile of Haemonetics’ VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures
Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)
Reflow Medical Announces U.S. Launch of Next-Generation Cora Flex® and Cora Force® Torqueable Microcatheters
Popular
- No commented posts yet